近期，资本市场交投氛围活跃，机构亦加快调研节奏，深入挖掘A股上市公司投资价值与潜在机会。 iFinD数据显示，2026年以来，已有670家上市公司接受了券商、公募等机构集中调研，合计调研次数达984次。其中，大金重工 （002487.SZ）、迈瑞医疗（300760.SZ）、超捷股份（301005.SZ）等企业成为机构调研的热门标的，参与调研的机构数量均超百家。 从行业与概念维度看，电子、机械设备等行业数量最多，脑机接口、商业航天等概念受追捧。 年内670家公司获机构调研 机构调研的广度与深度，直接反映出资本市场对不同行业的关注程度。根据iFinD数据，今年以来，已有670家上市公司接受了各类机构 的调研。从行业分布来看，电子、机械设备、医药生物等行业数量居前，均有60家以上，电力设备、计算机、汽车、基础化工等行业也 有超过40家企业接受调研。 近期，国家电网宣布，"十五五"时期固定资产投资预计达到4万亿元，较"十四五"时期投资增长40%。电力设备行业成为券商调研最热方 向之一，涵盖光伏、风电、电网设备、电池等板块。其中，大金重工今年以来获得209家机构调研，帝科股份（300842.SZ）接受123家 机构调研 ...

南财智讯1月29日电，创新医疗发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-3300万元—-2600万元，同比预增64.88%—72.33%；预计2025年全年归属于上市公司股东的扣除非经 常性损益的净利润为-7500万元—-6800万元，同比预减14.14%—25.89%。业绩变动原因说明：1、本报 告期归属于上市公司股东的净利润出现同比上升，主要系：公司增持博灵脑机股权并将该公司纳入合并 报表范围，根据《企业会计准则第33号——合并财务报表》第四十八条的规定，确认了相应的投资收 益；李晔案件再审改判后，建华医院收到了法院返还的被执行款项，并由此确认了营业外收入。2、本 报告期扣除非经常性损益后的净利润出现同比下降，主要系：在医保政策以及医保支付标准持续调整的 行业背景下，康华医院、建华医院对短期盈利预期的不确定性进行了审慎评估，本报告期确认的递延所 得税资产同比减少，导致所得税费用出现同比上升。 ...

Core Viewpoint - Zhejiang Qiangnao Technology Co., Ltd. has reportedly submitted a confidential IPO application to the Hong Kong Stock Exchange, with CICC and UBS as joint sponsors, indicating a significant move towards public listing in the rapidly growing brain-computer interface (BCI) sector [1][3]. Company Overview - Founded in February 2015, Qiangnao Technology focuses on the development of non-invasive brain-computer interface technology, with products spanning smart bionics, health, and education [1]. - The company has launched several products, including a smart bionic hand, a brain-machine intelligent sleep device, and an attention training system [1]. Financing History - Qiangnao Technology completed a significant financing round in early January, raising approximately 2 billion RMB, marking it as the second-largest financing in the BCI field globally, after Neuralink [3]. - Since its inception, the company has completed six rounds of financing, including a notable $400 million Series A round in 2019 [3][4]. - The latest financing rounds include a $30 million Pre-B round and a $20 million Series B round in 2025 [4]. Market Trends - The BCI sector is experiencing rapid growth, with 26 financing events in 2025 totaling 1.778 billion RMB, a significant increase from 2024 [5]. - The global BCI market is projected to grow from approximately $2.6 billion in 2024 to $2.9 billion in 2025, with a further increase to $3.3 billion by 2026 [5]. - In China, the BCI market is expected to reach 3.8 billion RMB in 2025, up from 3.2 billion RMB in 2024 [5]. Policy Support - The Chinese government is actively promoting the BCI industry, with policies aimed at fostering innovation and establishing industry clusters by 2027 and 2030 [7]. - The national strategy includes BCI as a key area for economic growth, alongside other advanced technologies [7]. Industry Outlook - Analysts predict that the BCI industry is on the verge of significant growth, driven by commercial advancements and policy support [8]. - The transition from laboratory research to commercialization is expected to accelerate, particularly with the anticipated production scale-up by Neuralink [8].

Core Viewpoint - The recent approval of two medical device industry standards by the National Medical Products Administration (NMPA) marks a significant step towards the high-quality development of brain-computer interface (BCI) technology in China, providing essential support for the industry [1][4]. Industry Development - The BCI market in China is projected to reach 3.2 billion yuan in 2024, with a year-on-year growth of 18.8%, and is expected to grow to 5.58 billion yuan by 2027, reflecting a growth rate of 20% [3]. - As of early 2026, there are 2,041 BCI-related patents in China, with over 90% being invention patents, indicating a strong focus on innovation within the industry [3]. Standardization Efforts - The establishment of a standard system is crucial for addressing issues such as terminology confusion, fragmented technology layout, and lack of unified regulations, which currently hinder the rapid development of the BCI industry [3][4]. - The two newly approved standards specifically target medical devices for stroke and spinal cord injury rehabilitation, addressing urgent needs for regulation in the BCI medical device sector [4]. Policy Support - The "14th Five-Year Plan" identifies BCI as one of six future industries, highlighting its potential as a new engine for economic growth in China [5]. - The NMPA has prioritized the approval of implantable BCI medical devices, expediting the market entry of innovative products [6]. Market Dynamics - The BCI industry is entering a critical commercialization phase, driven by policy support, technological advancements, and clinical breakthroughs [6][7]. - The capital market shows strong interest in BCI, with significant increases in stock prices and investment events, indicating a robust growth outlook for the sector [7]. Future Directions - The future applications of BCI in the medical field are expected to expand into active scenarios for neuro-regulation, multi-modal integration, and potentially enhancing functions beyond mere rehabilitation [8].

Group 1 - The core viewpoint highlights that the innovation drug sector is experiencing high prosperity, with a continuous net inflow of nearly 500 million yuan into the Guotai Innovation Drug ETF (589720) over the past 10 days, despite a recent pullback of over 1.3% [1] - Guotai Haitong recommends focusing on Pharma, which is expected to undergo a revaluation, and Biopharma/Biotech, which is gradually realizing its innovative pipeline and entering a performance ramp-up phase [1] - The report emphasizes investment opportunities in CXO and upstream pharmaceutical sectors benefiting from innovation and recovery, as well as in medical devices with significant engineering advantages and successful overseas expansion [1] Group 2 - Recent supportive policies from the National Healthcare Security Administration, including the release of guidelines for pricing projects related to surgical and therapeutic auxiliary operations, are expected to benefit relevant innovative surgical projects [1] - The medical device sector is seeing frequent catalysts, with investment opportunities emerging in areas such as overseas expansion, brain-computer interfaces, and AI medical applications [1] - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which has a daily price fluctuation limit of 20% and includes listed companies engaged in innovative drug research and development, covering biopharmaceuticals, chemical drugs, and traditional Chinese medicine [1]

Core Viewpoint - The article highlights the positive performance of the ChiNext Medical ETF (国泰, 159377) amid supportive policies and a focus on innovation within the pharmaceutical and medical device sectors [1]. Group 1: Industry Policies and Innovations - Recent supportive policies are continuously emerging, leading to a recommendation for innovative drugs and medical devices along with their supply chains [1]. - The high demand for innovative drugs is noted, with a recommendation for Pharma companies that are expected to see a revaluation, as well as Biopharma/Biotech firms whose performance is entering a growth phase [1]. Group 2: Investment Opportunities - The report suggests investment in CXO and upstream pharmaceutical companies that benefit from innovation and a recovery in market conditions [1]. - In the medical device sector, companies that excel in engineering and have successful overseas expansions are recommended for investment [1]. Group 3: Future Catalysts - The report mentions that from 2026 onwards, there will be frequent catalysts in the medical device sector, with a focus on investment opportunities in overseas markets, brain-computer interfaces, and AI in healthcare [1]. Group 4: ETF Performance - The ChiNext Medical ETF (国泰, 159377) tracks the Innovation Medicine Index (创医药指数, 399275), which has a daily price fluctuation limit of 20% and includes listed companies involved in the research, production, and related services of innovative drugs [1].

Core Insights - The article presents a roadmap for China's technological advancement, highlighting the rapid transformation in various sectors such as quantum computing, brain-machine interfaces, embodied intelligence, and low-altitude economy [5] Group 1: Overview of the Ranking - The "Touzhong List: Sharp Company Ranking" identifies 100 innovative and high-potential companies across sectors like semiconductors, embodied intelligence, artificial intelligence, low-altitude economy, commercial aerospace, new energy, and healthcare [3] - Over half of the listed companies are in the B round or earlier financing stages, with notable examples like Jike Technology and Zhiren Medical, which have gained capital interest due to their technological barriers and practical applications [3] Group 2: Regional Distribution - Beijing, Shanghai, and Shenzhen lead with 32, 16, and 16 companies respectively, accounting for 64% of the total listed companies, up from 57% [4] - Beijing has seen a significant increase in AI and embodied intelligence companies, doubling its number of listed firms due to resource concentration in Zhongguancun Science City and Yizhuang Industrial Park [4] - Other cities, including Hangzhou, Guangzhou, Hefei, and Huzhou, also contributed to the list, indicating a nationwide spread of innovation activities [4] Group 3: Characteristics of Listed Companies - A notable feature of this year's list is the inclusion of several future industry companies in cutting-edge fields such as embodied intelligence, brain-machine interfaces, and synthetic biology [4] - These companies are moving beyond mere technological validation to accelerate industrialization through a dual approach of "technology + application scenarios" [4]

Core Viewpoint - The China Science and Technology News Society has released the "Top Ten Technology Buzzwords for 2025," highlighting key areas of technological advancement and innovation in the country [1]. Group 1: Technology Buzzwords - The selected buzzwords for 2025 include: AI governance, embodied intelligence, controllable nuclear fusion, brain-computer interfaces, commercial aerospace, deep-sea technology, deep space exploration, silver-haired technology, intelligent agents, and Chinese innovation [1]. Group 2: Selection Process - The evaluation process for the buzzwords involved a combination of big data screening and extensive collection of suggestions, leading to a candidate list that was finalized through the assessment of academicians, technology experts, media leaders, and science popularization experts [1].

Group 1 - The core focus of Tianjin's government work report is to "comprehensively strengthen the support and leadership of technological innovation," which is one of the eight key tasks for the year [1] - Tianjin aims to cultivate a "scientific innovation rainforest" by integrating education, technology, and talent to transform these diverse elements into new productive forces for development [1][2] - The report emphasizes the establishment of a mechanism for collaboration with central research institutions and universities in Tianjin to promote shared research facilities and team building [2] Group 2 - The report outlines the goal of establishing national innovation centers in brain-machine interfaces and blood disease medicine, highlighting Tianjin's commitment to key technological breakthroughs in areas such as artificial intelligence and synthetic biology [2] - An innovative case presented by a representative involves producing malic acid from agricultural waste, showcasing the practical applications of technological innovation in everyday life [4] - The Tianjin government is focusing on nurturing core areas within the innovation ecosystem, particularly the Tianjin Kai High Education Science and Technology Park, which is expected to lead innovation and development [6] Group 3 - The report describes the strategy of "precision drip irrigation" for nurturing new industries such as information technology, biomedicine, and new energy materials, emphasizing the importance of a supportive ecosystem for technological enterprises [6][8] - Key measures include the development of research and development services, knowledge property rights, and the establishment of joint laboratories, with a target of surpassing 230 billion yuan in technology contract transactions [8] - The report highlights the importance of financial support for technology innovation, including the development of various funds and promoting the listing of more technology-driven companies [8]

Core Insights - Fourier is exploring the deep integration of brain-machine interfaces (BMIs) with embodied intelligence, launching a rehabilitation solution called "Brain-Machine Embodied Rehabilitation Port" aimed at wellness scenarios [1] - The company has been a pioneer in the rehabilitation robotics industry in China, focusing on wellness scenarios as a key application area for embodied intelligence [1] - Traditional rehabilitation methods face challenges such as low patient engagement and difficulty in quantifying training effectiveness, with existing devices primarily focusing on peripheral execution rather than central brain involvement [1] Group 1 - The integration of BMIs allows rehabilitation treatments to operate on a closed-loop system based on "brain intention," marking a significant advancement in rehabilitation technology [1] - Fourier has been exploring the combination of BMIs with exoskeleton robots since 2017, achieving concept validation but facing engineering challenges that limited clinical application [1][2] - Recent advancements in BMI hardware have led to lighter, modular devices with improved interference resistance and accuracy, expanding signal acquisition methods beyond traditional EEG to include near-infrared and multi-channel ultrasound [2] Group 2 - The use of AI algorithms enables real-time classification and interpretation of complex brain signals, facilitating precise intention recognition and driving robotic lower limb training [2] - Fourier has established over 300 rehabilitation departments across the country, targeting various levels of medical institutions and wellness communities [2] - A collaborative initiative called the "Brain-Machine Embodied Data Engine Joint Innovation Plan" has been launched, involving multiple academic and research institutions to support the integration of BMIs with embodied intelligent systems [3]